Acurx Pharmaceuticals, Inc.'s SEC filings document a late-stage biopharmaceutical issuer developing antibiotics for difficult-to-treat Gram-positive bacterial infections. Registration statements describe securities offerings, resale registration mechanics, common stock, warrants and the company's status as an emerging growth company and smaller reporting company.
ACXP's Form 8-K filings record material events tied to capital structure, governance and compensation, including amendments to authorized common shares and executive and director compensation arrangements. The filings also cover Nasdaq-listed common stock, operating and financial results, material agreements, shareholder voting matters and risk disclosures associated with antibiotic research and development.
Acurx Pharmaceuticals reported a Q1 2026 net loss of $1.68 million, an improvement from $2.15 million a year earlier, as both research and development and general and administrative expenses declined. R&D fell to $0.34 million and G&A to $1.37 million, reflecting lower manufacturing, consulting, professional, and legal costs.
Cash was $9.25 million and working capital $7.0 million as of March 31, 2026, with cumulative losses of about $77.0 million. Management states this cash will not fund operations for 12 months from issuance of the financial statements and raises “substantial doubt” about the company’s ability to continue as a going concern, expecting continued losses and relying on additional equity and grant funding.
The company continues developing ibezapolstat for C. difficile infection, launching a new open-label pilot trial in recurrent CDI and planning Phase 3 registration work. Liquidity efforts include an equity line of credit with Lincoln Park, under which $7.3 million has been raised, and an April 2026 registered direct offering and concurrent private placement providing approximately $2.5 million in gross proceeds plus new warrants.
Acurx Pharmaceuticals, Inc. is registering 1,300,000 shares of common stock for resale by Lincoln Park Capital under an existing equity purchase agreement. These shares relate to an up to $12.0 million equity line, of which $7.3 million has already been drawn through sales of 1,835,000 shares.
Acurx will not receive proceeds from Lincoln Park’s resales, but may receive up to an additional $4.7 million from future share sales to Lincoln Park at its discretion. As of April 20, 2026, 4,278,492 shares were outstanding; if all 1,300,000 shares were issued, they would represent about 23% of outstanding stock. The prospectus highlights dilution and stock price pressure risks, alongside recent financing of approximately $2.5 million in an April 2026 registered direct offering and progress on its ibezapolstat program for recurrent C. difficile infection.
Acurx Pharmaceuticals, Inc. is filing an S-1 to register the resale of up to 1,650,170 shares of common stock issuable upon exercise of Series H warrants with a $2.78 per share exercise price. Only selling stockholders will receive resale proceeds; Acurx would receive up to about $4.6 million if all warrants are exercised for cash. These Series H warrants were issued in an April 2026 private placement tied to a concurrent $2.5 million registered direct offering. Acurx is a late-stage biopharmaceutical company developing Gram-positive targeted antibiotics and its stock trades on Nasdaq under the symbol ACXP.
Acurx Pharmaceuticals director Carl Sailer received a stock option grant tied to his service on the company’s board. The award covers 2,150 options for Common Stock at an exercise price of $2.36 per share.
The options were granted as part of Acurx’s Director Compensation Policy and will fully vest on April 20, 2027. Following this award, Sailer holds stock options for 2,150 underlying shares, which are scheduled to expire on April 20, 2036.
Acurx Pharmaceuticals director Jack H. Dean received a compensatory stock option award for service on the company’s board. The grant covers 2,150 shares of common stock at an exercise price of $2.36 per share, expiring on April 20, 2036.
The option was granted at no cost and is scheduled to vest in full on April 20, 2027 under Acurx’s Director Compensation Policy. This Form 4 reports an option grant only; it does not show any open‑market purchases or sales of Acurx common stock by the director.
Acurx Pharmaceuticals director James J. Donohue received a stock option grant covering 2,150 shares of common stock as board compensation. The option has an exercise price of $2.36 per share, vests on April 20, 2027, and expires on April 20, 2036. Following the grant, he holds 2,150 stock options directly.
Acurx Pharmaceuticals, Inc. director Thomas L. Harrison received a stock option award as compensation for service on the company’s board of directors. The grant covers 2,150 stock options for common stock at an exercise price of $2.36 per share.
The options were awarded at no upfront cost and will vest on April 20, 2027, meaning they become exercisable on that date. The options are scheduled to expire on April 20, 2036 if not exercised. Following this grant, Harrison holds stock options covering 2,150 shares directly.
Acurx Pharmaceuticals, Inc. director Joseph C. Scodari received a stock option grant related to his service on the company’s board. The award covers 2,150 stock options for common stock at an exercise price of $2.36 per share, with all options vesting on April 20, 2027.
The options expire on April 20, 2036. After this grant, Scodari holds 2,150 stock options directly, reflecting a compensation-related award rather than an open‑market share purchase or sale.